MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026

MiNK Therapeutics, Inc.

Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.
Cash $14.3M at quarter-end; raised $1.2M post-quarter; runway extended through 2026.
Clinical data: durable complete remissions >2 years in refractory cancers; no Grade 3+ CRS/neurotoxicity.
Launching Phase 1 GvHD study with UW-Madison, funded by NIH and philanthropy.
Appointed Dr. Terese Hammond as Head of Inflammatory and Pulmonary Diseases, Dr. Holcomb to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.